Search

Your search keyword '"Sanjuanbenito, Alfonso"' showing total 19 results
Start Over Author "Sanjuanbenito, Alfonso" Publication Year Range Last 3 years
19 results on '"Sanjuanbenito, Alfonso"'

1. The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants

Author

Cristina-Marianini-Rios, Sanchez, María E. Castillo, de Paredes, Ana García García, Rodríguez, Mercedes, Barreto, Emma, López, Jorge Villalón, Fuentes, Raquel, Beltrán, María Muñoz, Sanjuanbenito, Alfonso, Lobo, Eduardo, Caminoa, Alejandra, Ruz-Caracuel, Ignacio, Durán, Sergio López, Olcina, José Ramón Foruny, Blázquez, Javier, Sequeros, Enrique Vázquez, Carrato, Alfredo, Ávila, Jose Carlos Martínez, and Earl, Julie

Published
2024
Full Text
View/download PDF

2. The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer

Author

Earl, Julie, Fuentes, Raquel, Sanchez, María E. Castillo, de Paredes, Ana García García, Muñoz, María, Sanjuanbenito, Alfonso, Lobo, Eduardo, Caminoa, Alejandra, Rodríguez, Mercedes, Barreto, Emma, López, Jorge Villalón, Ruz-Caracuel, Ignacio, Durán, Sergio López, Olcina, José Ramón Foruny, Sánchez, Bárbara Luna, Páez, Sonia Camaño, Torres, Ana, Blázquez, Javier, Sequeros, Enrique Vázquez, and Carrato, Alfredo

Published
2024
Full Text
View/download PDF

4. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

Author

Rojas-Holguín, Adela, Fondevila-Campo, Constantino, Sanjuanbenito, Alfonso, Fabregat-Prous, Joan, Secanella-Medayo, Luís, Rotellar-Sastre, Fernando, Pardo-Sánchez, Fernando, Prieto-Calvo, Mikel, Marín-Ortega, Héctor, Sánchez-Cabús, Santiago, Diez-Valladares, Luis, Alonso-Casado, Óscar, González-Serrano, Carmen, Rodríguez-Sanjuan, Juan Carlos, García-Plaza, Gabriel, Jaén-Torrejimeno, Isabel, Suárez-Muñoz, Miguel Ángel, Becerra-Massare, Antonio, Rio, Paula Senra-del, Pando, Elizabeth, López-Andújar, Rafael, Muñoz-Forner, Elena, Rodriguez-López, Mario, Pereira, Fernando, Serrablo-Requejo, Alejandro, Turrión, Víctor Sánchez, Garrido, Manuel Jiménez, Burdío, Fernando, Martín-Pérez, Elena, Estevan-Estevan, Rafael, López-Guerra, Diego, Castell-Gómez, José, Salinas-Gómez, Javier, López-Baena, José Ángel, López-Ben, Santiago, Solar-García, Lorena, Pérez-Alonso, Alejandro J., Martínez-Insfran, Luis Alberto, Blas, Juan Luis, Cornejo, Marian, Gutierrez-Calvo, Alberto, Pozo, Carlos Domingo-del, Ochando-Cerdan, Federico, Muñoz-Bellvís, Luis, Rebollar-Saenz, José, Sánchez, Belinda, Jover, José María, Gómez-Bravo, Miguel Ángel, Ramia, José M., and Blanco-Fernández, Gerardo

Published
2024
Full Text
View/download PDF

7. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)

Author

Blanco-Fernández, Gerardo, Fondevila-Campo, Constantino, Sanjuanbenito, Alfonso, Fabregat-Prous, Joan, Secanella-Medayo, Luís, Rotellar-Sastre, Fernando, Pardo-Sánchez, Fernando, Prieto-Calvo, Mikel, Marín-Ortega, Héctor, Sánchez-Cabús, Santiago, Diez-Valladares, Luis, Alonso-Casado, Óscar, González-Serrano, Carmen, Rodríguez-Sanjuan, Juan Carlos, García-Plaza, Gabriel, Jaén-Torrejimeno, Isabel, Suárez-Muñoz, Miguel Ángel, Becerra-Massare, Antonio, Rio, Paula Senra-del, Pando, Elizabeth, López-Andújar, Rafael, Muñoz-Forner, Elena, Rodriguez-López, Mario, Pereira, Fernando, Serrablo-Requejo, Alejandro, Turrión, Víctor Sánchez, Garrido, Manuel Jiménez, Burdío, Fernando, Martín-Pérez, Elena, Estevan-Estevan, Rafael, López-Guerra, Diego, Castell-Gómez, José, Salinas-Gómez, Javier, López-Baena, José Ángel, López-Ben, Santiago, Solar-García, Lorena, Pérez-Alonso, Alejandro J., Martínez-Insfran, Luis Alberto, Blas, Juan Luis, Cornejo, Marian, Gutierrez-Calvo, Alberto, Pozo, Carlos Domingo-del, Ochando-Cerdan, Federico, Muñoz-Bellvís, Luis, Rebollar-Saenz, José, Sánchez, Belinda, Jover, José María, Gómez-Bravo, Miguel Ángel, Ramia, José M., and Rojas-Holguín, Adela

Published
2022
Full Text
View/download PDF

8. Abstract A012: The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): Genetic testing and follow-up of high risk individuals

Author

Melian, Emma, primary, de Paredes, Ana García García, additional, Rodríguez, Mercedes, additional, López, Jorge Villalón, additional, Muñoz, María, additional, Blaquez, Javier, additional, Ruz, Ignacio, additional, Sanjuanbenito, Alfonso, additional, Lobo, Eduardo, additional, Lopéz, Victoria, additional, Ponce, Carmen Guillen, additional, Foruny Olcina, José Ramón, additional, Durán, Sergio López, additional, Carrato, Alfredo, additional, and Earl, Julie, additional

Published
2024
Full Text
View/download PDF

9. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Author

Díaz-Alejo, Jesús Frutos, primary, April-Monn, Simon, additional, Cihova, Marina, additional, Buocikova, Verona, additional, Villalón López, Jorge, additional, Urbanova, Maria, additional, Lechuga, Carmen G., additional, Tomas, Miroslav, additional, Dubovan, Peter, additional, Sánchez, Bárbara Luna, additional, Páez, Sonia Camaño, additional, Sanjuanbenito, Alfonso, additional, Lobo, Eduardo, additional, Romio de la Heras, Estefanía, additional, Guerra, Carmen, additional, de la Pinta, Carolina, additional, Barreto Melian, Emma, additional, Rodríguez Garrote, Mercedes, additional, Carrato, Alfredo, additional, Ruiz-Cañas, Laura, additional, Sainz,, Bruno, additional, Torres, Ana, additional, Smolkova, Bozena, additional, and Earl, Julie, additional

Published
2023
Full Text
View/download PDF

10. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

Author

López-Gil, Juan Carlos, García-Silva, Susana, Ruiz-Cañas, Laura, Navarro, Diego, Palencia-Campos, Adrián, Giráldez-Trujillo, Antonio, Earl, Julie, Dorado, Jorge, Gómez-López, Gonzalo, Monfort-Vengut, Ana, Alcalá, Sonia, Gaida, Matthias M, García-Mulero, Sandra, Cabezas-Sáinz, Pablo, Batres-Ramos, Sandra, Barreto, Emma, Sánchez-Tomero, Patricia, Vallespinós, Mireia, Ambler, Leah, Lin, Meng-Lay, Aicher, Alexandra, García García de Paredes, Ana, de la Pinta, Carolina, Sanjuanbenito, Alfonso, Ruz-Caracuel, Ignacio, Rodríguez-Garrote, Mercedes, Guerra, Carmen, Carrato, Alfredo, de Cárcer, Guillermo, Sánchez, Laura, Nombela-Arrieta, César, Espinet, Elisa, Sanchez-Arevalo Lobo, Víctor Javier, Heeschen, Christopher, and Sainz, Bruno

Abstract

ObjectivePancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant ‘stem-like’ cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies.DesignWe used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitrococulture assays, in vivomouse and zebrafish tumorigenesis studies, and in silicodatabase approaches were performed.ResultsUsing the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC.ConclusionsThis study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy.

Published
2024
Full Text
View/download PDF

11. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)

Author

Universidad de Sevilla. Departamento de Cirugía, Blanco Fernández, Gerardo, Fondevila Campo, Constantino, Sanjuanbenito, Alfonso, Rodríguez López, Mario, Pérez Alonso, Alejandro J., Gómez Bravo, Miguel Ángel, Rojas Holguín, Adela, Universidad de Sevilla. Departamento de Cirugía, Blanco Fernández, Gerardo, Fondevila Campo, Constantino, Sanjuanbenito, Alfonso, Rodríguez López, Mario, Pérez Alonso, Alejandro J., Gómez Bravo, Miguel Ángel, and Rojas Holguín, Adela

Abstract

Background: Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study is to evaluate the short and long-term results of a multicenter series in order to determine the effect of surgical treatment on the prognosis of these patients. Methods: Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases, from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical char- acteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on short and long-term evolution after pancreatic resection were collected. Results: The study included 116 patients. The mean time between nephrectomy and pancreatic metas- tases’ resection was 87.35 months (ICR: 1.51e332.55). Distal pancreatectomy was the most performed technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo greater than IIIa in 14 %). The median follow-up time was 43 months (13e78). Overall survival (OS) rates at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and 5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free interval of less than 10 years (2.05 [1.13e3.72], p 0.02) and a history of previous extrapancreatic metastasis (2.44 [1.22e4.86], p 0.01). Conclusions: Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve higher overall survival and disease-free survival, even if extrapancreatic metastases were previously removed. The existence of intrapancreatic multifocal compromise does not always warrant the perfor- mance of a total pancreatectomy in order to improve survival.

Published
2022

13. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID)

Author

Blanco Fernández, Gerardo, Fondevila Campo, Constantino, Sanjuanbenito, Alfonso, Rodríguez López, Mario, Pérez Alonso, Alejandro J., Gómez Bravo, Miguel Ángel, Rojas Holguín, Adela, and Universidad de Sevilla. Departamento de Cirugía

Subjects
Pancreatectomy, Recurrence, Metastases, Renal cell carcinoma
Abstract

Background: Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study is to evaluate the short and long-term results of a multicenter series in order to determine the effect of surgical treatment on the prognosis of these patients. Methods: Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases, from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical char- acteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on short and long-term evolution after pancreatic resection were collected. Results: The study included 116 patients. The mean time between nephrectomy and pancreatic metas- tases’ resection was 87.35 months (ICR: 1.51e332.55). Distal pancreatectomy was the most performed technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo greater than IIIa in 14 %). The median follow-up time was 43 months (13e78). Overall survival (OS) rates at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and 5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free interval of less than 10 years (2.05 [1.13e3.72], p 0.02) and a history of previous extrapancreatic metastasis (2.44 [1.22e4.86], p 0.01). Conclusions: Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve higher overall survival and disease-free survival, even if extrapancreatic metastases were previously removed. The existence of intrapancreatic multifocal compromise does not always warrant the perfor- mance of a total pancreatectomy in order to improve survival.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results